• Patient's Derived Organoids for Drug Screening in Glioblastoma

  NCT06781372

  Not yet recruitingInterventionalNot ApplicableUpdated Mar 13, 2025
• Patient-derived Glioma Stem Cell Organoids

  NCT04868396

  Active, not recruitingObservationalUpdated Nov 20, 2024
• Drug Response Testing and Repurposing Using Glioblastoma Organoid

  NCT06782984

  RecruitingObservationalUpdated Jan 20, 2025
• Grafts of GSCs Into Brain Organoids for Testing Anti-invasion Drugs

  NCT05772741

  Unknown statusInterventionalNot ApplicableUpdated Mar 16, 2023
• A Living Tissue Bank of Patient-Derived Organoids From Glioma Tumors

  NCT04865315

  RecruitingObservationalUpdated Jan 27, 2026
• Prospective Multicenter Study Evaluating Feasibility and Efficacy of Tumor Organoid-based Precision Medicine in Patients With Advanced Refractory Cancers

  NCT05267912

  RecruitingInterventionalNot ApplicableUpdated Jun 26, 2026

ClinicalTrials.gov ID

NCT07029100

Lead Sponsor

Centre Henri BecquerelOTHER

Overall Status

Not yet recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

30Estimated

Last Update Posted

Jun 19, 2025Actual

Start Date

Jul 1, 2025Estimated

Primary Completion Date

Jul 1, 2027Estimated

Completion Date

Jul 1, 2029Estimated

Official Title

Feasibility of ORGAnoids in Routine Clinical Practice for Molecular Analysis of the GLIOvascular Niche in Patients With Primary Brain Tumors.

Brief Summary

The main goal of ORGA-GLIO trial is to establish the feasibility in routine clinical practice of ex-vivo organoid cultures composed of tumor cells within their microenvironment (glioblastoma organoid - GBO) and intra- and peri-tumoral blood vessels (blood vessel organoid - BVO), derived from perioperative samples obtained during complete or partial surgical resection in patients with newly diagnosed glioblastoma.

Detailed Description

The ORGA-GLIO study will be conducted in two stages:

First stage: Establishment of the clinical-biological collection and addressing the primary objective.

Step 1: Generation of tumor organoids (Glioblastoma Organoids - GBO), vascular organoids (Blood Vessel Organoids - BVO), and cell lines.

Step 2: Phenotypic and molecular analyses of tumor and vascular organoids up to 7 days.

Second stage: Utilization of the biological collection of organoids and blood samples.

Utilization of the organoid collection and investigation of associations between the molecular and phenotypic and clinical and survival data collected during patient follow-up visits.

Correlation of organoid evolution under experimental treatment procedure and evolution of plasma-based biomarker from corresponding patients and along first-line treatment schedule.

All patients will be planned to receive standard of care for glioblastoma after resection, namely radiotherapy+temozolomide and TTFields.

• Glioblastoma

• Ex-vivo organoid culture

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Patient, male or female, adult (age ≥ 18 years),
• Suspected of having a high-grade glioma based on preoperative multimodal MRI,
• With an indication for tumor resection surgery,
• And in a clinical condition suitable to undergo adjuvant treatment consisting of radiotherapy (normo- or hypo-fractionated) combined with temozolomide, with or without low-frequency electric fields (Tumor-Treating Fields®).

Exclusion Criteria:

• Current tumor pathology or history of tumor pathology in remission for less than 2 years
• Pregnant or breastfeeding women,
• Patients unable to understand the study for any reason or unable to comply with trial requirements (language barriers, psychological or geographical issues, etc.).

Primary Purpose

Basic Science

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Centre Henri BecquerelOTHER

maxime.fontanilles@chb.unicancer.fr+33276673091

olivier.langlois@chu-rouen.fr+33232888042